Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention James McArthur, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.9 for the broader beat in this window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention James McArthur, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.9 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. OmniAb appears in 1 tracked Finance story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 98 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OmniAb. Shared-story counts are live from our verified record — not editorial picks.
OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors. While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.
OmniAb is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
